QUESTIONS AND ANSWERS ABOUT THE SHAREHOLDER MEETING
The questions and answers below highlight only selected information from this proxy statement and only briefly address some commonly asked
questions about the Shareholder Meeting (as defined below) and the proposals to be presented at the Shareholder Meeting. The following questions and answers do not include all the information that is important to DHC shareholders. Shareholders are
urged to read carefully this entire proxy statement, including the other documents referred to herein, to fully understand the proposal to be presented at the Shareholder Meeting and the voting procedures for the Shareholder Meeting, which will be
held on March 3, 2023, at 9:00 a.m., Eastern Time. The Shareholder Meeting will be held at the offices of Cooley LLP, 55 Hudson Yards, New York, NY 10001, and via a virtual meeting, or at such other time, on such other date and at such other
place to which the meeting may be postponed or adjourned (the Shareholder Meeting). You can participate in the meeting, vote, and submit questions via live webcast by visiting https://www.cstproxy.com/dhcacquisition/2023.
Q: Why am I receiving this proxy statement?
DHC is a blank check company incorporated as a Cayman Islands exempted company on December 22, 2020. DHC was incorporated for the purpose
of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses or entities.
On March 4, 2021, DHC consummated its Initial Public Offering of 30,000,000 units, at an offering price of $10.00 per unit and a private
placement with DHC Acquisition LLC of 6,000,000 private placement warrants at a price of $1.00 per warrant. On March 5, the Company consummated a partial exercise by the underwriters of the initial public offering of their over-allotment option
for 945,072 units (the Overallotment Units) and 126,010 private placement warrants (together with the private placement warrants offered and sold in our initial public offering, the Private Placement Warrants).
The net proceeds from our initial public offering and the Overallotment Units together with certain of the proceeds from the Private Placement, $309,450,720 in the aggregate, were placed in a trust account (the Trust Account)
established for the benefit of the Companys public shareholders and the underwriters of the Initial Public Offering with Continental Stock Transfer & Trust Company acting as trustee.
Like most blank check companies, DHCs amended and restated memorandum and articles of association (the Memorandum and Articles
of Association) provide for the return of the Initial Public Offering proceeds held in trust to the holders of Class A ordinary shares, par value $0.0001 per share (the Class A Ordinary Shares or
the Public Shares) sold in the Initial Public Offering if there is no qualifying business combination(s) consummated on or before March 4, 2023 (the Termination Date).
Without the Charter Extension, DHC will not be able to complete an initial business combination (a Business Combination).
DHC believes that it is in the best interests of DHCs shareholders to continue DHCs existence until December 4, 2023 if necessary in order to allow DHC additional time to complete a Business Combination and is therefore holding this
Shareholder Meeting.
Q: When and where will the Shareholder Meeting be held?
The Shareholder Meeting will be held on March 3, 2023, at 9:00 a.m., Eastern Time, at the offices of Cooley LLP, 55 Hudson Yards, New York, NY
10001, and via a virtual meeting, or at such other time, on such other date and at such other place to which the meeting may be postponed or adjourned.
Shareholders may attend the Shareholder Meeting in person. However in view of the ongoing COVID-19
pandemic, we are taking precautionary measures and therefore encourage you to attend the Shareholder Meeting virtually. You can participate in the meeting, vote, and submit questions via live webcast by visiting
https://www.cstproxy.com/dhcacquisition/2023.
5